ETON Eton Pharmaceutcials, Inc. Common Stock PHARMACEUTICAL PREPARATIONS Best Pharmaceutical Stocks 2026 →

Eton Pharmaceutcials (ETON) Stock: Buy, Sell, or Hold?

$68.94
+1.40 (+2.07%) β–²
5d: +35.92% 30d: +29.27% 90d: +68.96%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (20%)
Quality Score
49/100
Position
EXTENDED
30-Day Fair Range
$48.89 – $57.52
Position: EXTENDED
Forward P/E & Valuation
20.4x FAIR
vs 18.5x historical avg
Wall Street Target
$78.00
+15.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$47.03 / $70.64
Trend: Uptrend
πŸ’‘Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: ETON is 19.8% above its trading range ($57.52). Market expects 3.4% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.

Get Alerted When ETON Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$119.07
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$73.93
6.8% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.5x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ETON is currently trading at $68.94, which is considered extended relative to its 30-day fair value range of $48.89 to $57.52. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.4) compared to its historical average (18.5). At these levels, the market is pricing in 3.4% annual earnings growth.

Technical Outlook: Technically, ETON is in a uptrend. The price is approaching resistance at $70.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: ETON scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $78.00 (+15.5%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $48.89 - $57.52
Company Quality Score 49/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 20.0%

Trading Range & Key Levels

30-Day Trading Range $48.89 - $57.52
Current vs Trading Range EXTENDED
Support Level $47.03
Resistance Level $70.64
Current Trend Uptrend
Technical data as of Nov 11, 2026

Quantitative Signal Breakdown

  • BEARISH: Price significantly overextended (+19.8% above its trading range)
  • BEARISH: Weak technical setup (15/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading below Wall St target ($78.00)
  • BULLISH: Expecting earnings turnaround to 3.4% growth with 157.9% revenue growth
  • WARNING: Composite score 49/100 in the bottom quintile β€” this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 20.44
Wall Street Target $78.00 (+15.5%)
Revenue Growth (YoY) 157.9%
Earnings Growth (YoY) -12.6%
Profit Margin 35.4%
Valuation Premium vs History +3.4% premium
PE vs Historical 20.4 vs 18.5 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +3.4% (market-implied from PE analysis)
1-Year Target $69.84 (+3%)
2-Year Target $72.21 (+7%)
3-Year Target $74.67 (+11%)
3-Yr Target (if PE normalizes) (PE: 20β†’19) PE COMPRESSION $67.59 (+0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.4, Growth: 86.2%) $227.95 (+238%)
Base: (SPY PE: 19.9, Growth: 86.2%) $221.53 (+228%)
Bear: (PE: 16.9, Growth: 86.2%) $188.30 (+179%)
πŸ“ˆ Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (37x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Trailing PE: 36.56 | Current EPS (TTM): $1.76
Bull Case $132.92 (+97%)
Analyst growth 87.8%, PE expands to 40.2
Base Case $120.84 (+79%)
Market implied 87.8%, PE stable at 36.6
Bear Case $43.76 (-35%)
Severe decline -20.0%, PE contracts to 31.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share ETON Analysis

Share this live ETON analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (ETON)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary: Bullish sentiment prevails on StockTwits regarding $ETON as a follower expresses a request for a conversation with the company's management to discuss increasing shareholder value.
Key Retail Themes: potential for increased shareholder value
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 2:13 PM ET
Data refreshes hourly during market hours. Next update: 3:13 PM
πŸ”₯ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for ETON.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
29 analysts
$208 23 SELL
ALKS
Alkermes Plc
STRONG BUY
20 analysts
$58 33 SELL
UTHR
United Therapeutics Corp…
STRONG BUY
15 analysts
$687 52 HOLD
HROW
Harrow Health Inc
STRONG BUY
9 analysts
$63 53 HOLD
AQST
Aquestive Therapeutics I…
STRONG BUY
9 analysts
$9 51 HOLD

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive ETON Research Pages
ETON Technical Chart ETON Price Prediction ETON Intrinsic Value DCF ETON Earnings Date Why is ETON Moving Today? ETON Investment Advisor ETON Fair Price Analyzer ETON Competitors
Part B: Tradestie Flagship Market Scanners
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals